We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

EUROPE PLATELET RICH PLASMA MARKET ANALYSIS

Europe Platelet Rich Plasma Market, Product Type (Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others), By Origin (Autologous, Allogeneic/Homologues), By Application (Orthopaedics, Cosmetic Surgery and Dermatology, Neurosurgery, Cardiothoracic Surgery, General Surgery, Urology, Others), and By Country (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)-

  • Published In : Jun 2023
  • Code : CMI3346
  • Pages :90
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Market News

Europe Platelet Rich Plasma Market- Key Developments

Increasing inorganic growth strategies such as agreements and acquisitions by key players in the market is expected to drive the market groeth in the forecast period.

In May, 2022, Ester Medical, a pharmaceutical company announced that It had signed an agreement with Aesthetic Management for exclusive long-term marketing and distribution of Eclipse PRP and Tropocells in the U.S. market.

In March 2020, EmCyte Corporation, a manufacturer of medical devices announced the acquisition of all of the assets of Cellmedix Holdings, a biotechnology company, including its Centrepid Platelet Concentrator system. EmCyte’s acquisition of Cellmedix Holdings LLC’s (Cellmedix) assets could expands its intellectual property profile and product development capabilities.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.